

STOCK RECOMMENDATION - JANUARY 23RD, 2023

MARKET REVIEW

For the week ended January 20th, 2023.

- The local bourse ended the week positive as the All-Share Index advanced by 0.16% WoW to settle at 52,594.68pts. Consequently, the Year-to-Date return edged higher to 2.62% (vs. 2.46% in the prior week).
- Across sectors, performance was mixed as NGXBNK (-2.60% WoW), NGXCNSMRGDS (-0.40% WoW) and NGXINDUSTR (-1.06% WoW) recorded week-on-week losses, while NGXOILGAS (+0.35% WoW) and NGXINS (+1.78% WoW) closed positive.
- INTENEGINS led the gainers' chart (+28.95% WoW), while LIVESTOCK (-13.85% WoW) was the week's top loser.
 VERITASKAP and GEREGU ended the week as the most traded stocks by volume and value, respectively.

MARKET PREVIEW

For the week commencing January 23rd, 2023.

- While there are competing arguments for both sides of a positive and negative market outing this week, the latter seems to be more likely. For one, there is a likelihood of another hike (100bps in our view) in the Monetary Policy Rate at the Monetary Policy Committee meeting this week. In line with that and the higher amount on offer vis-à-vis the previous auctions, we think that yield would rise at the upcoming Treasury Bills Primary Market Auction which could make the equities market less attractive.
- Additionally, technical indicators, including the Relative Share Index (RSI) point and Price Action, point to a bearish market.
- Thus, we expect the market to close in the negative region this week.

THE WEEK THAT WAS (A REVIEW)

			Cur. Week	Prev. Week
NGXASI			52,594.68	52,512.48
Market Cap [NGN'trn]			28.65	28.60
Market Cap [USD 'bn]			62.07	61.98
Volume Traded [bn]			1.23	1.27
Value Traded [NGN'bn]			15.57	29.63
	NSEASI & Sect	toral Indices [Return Profile]		
	WtD	MtD	QtD	YtD
NGXASI	0.16%	2.62%	2.62%	2.62%
NGX-30	0.18%	3.06%	3.06%	3.06%
NGX-B10	-2.60%	5.10%	5.10%	5.10%
NGX-FB10	-0.40%	6.73%	6.73%	6.73%
NGX-OG5	0.35%	3.62%	3.62%	3.62%
NGX-INS10	1.78%	2.80%	2.80%	2.80%
NGX-IND	-1.06%	1.66%	1.66%	1.66%
Value (NGN)		Volume		
GEREGU	2,784,670,307	VERITASK	AP	349,567,680
AIRTELAFRI	2,078,184,365	STERLNB <i>A</i>	ANK	183,251,598
GTCO	1,767,026,294	GTCO		73,059,657
ZENITHBANK	1,655,055,889	ZENITHBA	NK	67,287,905
NESTLE	1,404,004,732	UBA		52,731,131
Highest Gainers	%	Highest Los	sers	%
INTENEGINS	28.95%	LIVESTOCK		-13.85%
MRS	13.48%	CILEASING		-10.00%
NAHCO	12.86%	UPDC		-9.62%
SUNUASSUR	12.12%	SOVRENINS	S	-7.14%
LOTUSHAL15	9.99%	INTBREW		-7.00%



	Fundamentals			Trailing					M	arket Perfor	mance	Valuation						
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2023 TP	Last Wk. Pr	UPP	RT
Financial Services																		
Banks																		
ACCESSCORP	0.09	15%	17%	1%	13.00	4.93	29.11	1.84x	0.31x	9.30	8.75	+6.47%	1.63	6.41	10.46	9.05	+16%	BUY
ETI	0.09	16%	21%	1%	14.81	6.50	30.80	1.85x	0.39x	12.05	10.60	+13.68%	2.22	6.38	14.14	12.05	+17%	BUY
FCMB	0.09	11%	11%	1%	11.14	1.52	13.31	2.64x	0.30x	4.07	3.51	+4.16%	2.60	1.64	4.26	4.01	+6%	HOLD
FIDELITYBK	0.08	12%	12%	1%	11.91	1.34	11.01	3.72x	0.45x	5.10	4.36	+14.94%	2.51	2.23	5.61	5.00	+12%	BUY
FBNH	0.09	23%	23%	2%	11.03	5.62	24.89	2.08x	0.47x	11.70	11.00	+7.34%	3.89	3.62	14.08	11.70	+20%	BUY
GTCO	0.08	37%	20%	3%	6.66	5.97	29.66	4.03x	0.81x	24.50	23.25	+4.78%	3.81	6.69	25.51	24.10	+6%	HOLD
STANBIC	0.09	27%	19%	2%	7.76	5.57	29.34	5.74x	1.09x	33.45	32.00	-4.33%	6.72	5.75	38.67	32.00	+21%	BUY
STERLNBANK	0.09	11%	12%	1%	12.15	0.61	5.19	2.56x	0.30x	1.55	1.40	+10.71%	2.62	0.58	1.53	1.55	-2%	HOLD
UBA	0.09	17%	16%	1%	10.76	3.80	24.15	2.13x	0.34x	8.35	7.95	+6.58%	1.91	4.93	9.43	8.10	+16%	BUY
UBN	0.08	10%	7%	1%	9.06	0.67	9.63	9.56x	0.66x	6.95	6.35	0.00%	9.13	0.75	6.84	6.40	+7%	HOLD
WEMABANK	0.09	9%	15%	1%	18.37	0.28	1.88	13.84x	2.08x	3.90	3.58	0.00%	4.22	0.84	3.55	3.90	-9%	HOLD
ZENITHBANK	0.07	35%	20%	3%	7.95	8.23	40.52	2.97x	0.60x	25.55	24.00	+1.88%	3.07	8.68	26.69	24.45	+9%	HOLD
Insurance																		
AIICO	0.30	10%	20%	3%	6.44	0.24	1.17	2.76x	0.56x	0.66	0.60	+10.17%	3.00	0.22	0.66	0.65	+2%	HOLD
LASACO	0.51	1%	1%	0%	2.19	0.05	6.33	21.50x	0.15x	1.10	0.89	+11.49%	8.45	0.14	1.16	0.97	+19%	BUY
MANSARD	0.65	2%	6%	2%	3.76	0.09	1.57	21.94x	1.28x	2.14	2.00	0.00%	6.05	0.44	2.66	2.00	+33%	BUY
NEM	0.73	19%	25%	14%	1.77	0.63	2.57	6.43x	1.58x	4.50	4.05	-10.00%	5.00	0.96	4.80	4.05	+19%	BUY
WAPIC	0.40	-7%	-6%	-3%	2.13	-0.05	0.86	-8.55x	0.52x	0.46	0.41	+12.50%	0.50	0.82	0.41	0.45	-9%	HOLD
CORNERST	0.39	16%	15%	6%	2.29	0.16	1.12	3.67x	0.54x	0.60	0.55	0.00%	3.68	0.17	0.61	0.60	+2%	HOLD
CUSTODIAN	0.47	11%	16%	5%	3.03	1.85	11.46	3.24x	0.52x	6.00	5.90	+0.84%	4.21	1.87	7.87	6.00	+31%	BUY

	Fundamentals					Trailing				Market Performance				Valuation					
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2023 TP	Last Wk. Pr	UPP	RT	
Other Financial Services																			
UCAP	0.04	61%	49%	2%	20.05	2.17	4.42	6.76x	3.31x	15.00	14.00	+4.64%	6.00	2.73	16.39	14.65	+12%	BUY	
AFRIPRUD	0.20	39%	18%	8%	2.22	0.79	4.52	7.69x	1.35x	6.20	5.90	+1.67%	8.50	0.96	8.12	6.10	+33%	BUY	
Consumer Staples & Discretionary																			
Breweries																			
GUINNESS	0.96	7%	15%	7%	2.37	6.55	42.43	10.57x	1.63x	69.30	69.30	0.00%	10.88	7.60	82.68	69.30	+19%	BUY	
NB	0.94	4%	10%	3%	3.02	2.34	22.43	19.88x	2.07x	47.95	41.00	+13.29%	18.15	2.91	52.82	46.45	+14%	BUY	
INTBREW	0.52	-3%	-5%	-2%	3.06	-0.24	5.06	-19.32x	0.92x	5.05	4.65	-1.06%	-	-	-	4.65	-	UR	
Packaged Foods & Meats																			
BUAFOODS	0.61	21%	39%	13%	3.05	74.62	192.97	1.00x	0.39x	74.50	71.50	+14.62%	12.29	4.39	53.95	74.50	-28%	SELL	
CADBURY	0.95	4%	15%	4%	3.72	1.28	8.26	9.46x	1.47x	12.25	11.90	+1.68%	8.85	1.57	13.86	12.10	+15%	BUY	
DANGSUGAR	0.78	9%	22%	7%	3.35	2.58	11.63	6.58x	1.46x	17.50	16.00	+5.92%	6.76	2.56	17.31	17.00	+2%	HOLD	
HONYFLOUR	0.90	-6%	-18%	-5%	3.29	-1.10	6.19	-2.13x	0.38x	2.43	2.20	-0.43%			-	2.33	-	UR	
FLOURMILL	1.46	2%	11%	2%	4.74	5.09	47.82	6.07x	0.65x	30.90	28.40	+8.80%	7.12	5.71	40.68	30.90	+32%	BUY	
NASCON	0.89	7%	21%	6%	3.35	1.30	6.21	8.17x	1.71x	11.10	10.50	-4.50%	8.90	1.48	13.17	10.60	+24%	BUY	
NESTLE	1.13	11%	113%	12%	9.10	58.80	52.07	18.37x	20.74x	1,100.00	1,080.00	-1.81%	23.68	64.26	1,521.84	1,080.10	+41%	BUY	
UACN	1.01	0%	0%	0%	2.22	0.00	16.75	2222.68x	0.60x	10.75	10.05	-1.95%	14.59	0.75	10.96	10.05	+9%	HOLD	
UNILEVER	0.72	-4%	-5%	-3%	1.84	-0.59	11.28	-19.21x	1.01x	11.60	11.40	-1.72%	38.02	0.33	12.46	11.40	+9%	HOLD	
Agricultural Products																			
ОКОМИОІЬ	0.78	38%	56%	29%	1.93	22.37	39.62	7.38x	4.16x	165.00	165.00	0.00%	9.40	20.42	191.95	165.00	+16%	BUY	
PRESCO	0.51	32%	59%	16%	3.67	23.05	39.06	6.54x	3.86x	150.80	137.50	+9.67%	7.22	23.87	172.34	150.80	+14%	BUY	
Household & Personal Products																			
PZ	0.70	3%	7%	2%	3.23	0.70	9.83	14.49x	1.03x	12.10	10.00	-11.01%	-	-	-	10.10	-	UR	
VITAFOAM	1.29	11%	32%	14%	2.34	3.94	12.36	5.56x	1.77x	21.90	20.45	+7.09%	-	-	-	21.90	-	UR	

Equity | Stock Recommendation

	Fundamentals			Trailing				Market Perf	ormance		Valuation							
	AT	NM	ROE	ROA	Lev	EPS	BVP	P/E	P/BV	Yr Hi	Yr Lo	YtD Return	Target PE	Exp. EPS	2023 TP	Last Wk. Pr	UPP	RT
Healthcare																		
Pharmaceuticals																		
MAYBAKER	0.77	11%	20%	9%	2.25	0.92	4.73	4.82x	0.94x	4.45	4.30	+3.49%	6.21	0.81	5.03	4.45	+13%	BUY
FIDSON	0.95	12%	30%	11%	2.63	2.11	7.04	4.44x	1.33x	9.79	9.23	+3.89%	4.34	3.62	15.70	9.35	+68%	BUY
GLAXOSMITH	0.92	4%	11%	4%	3.10	0.85	7.73	7.80x	0.86x	6.65	6.15	+8.13%	7.94	1.02	8.10	6.65	+22%	BUY
NEIMETH	0.42	-4%	-10%	-2%	5.87	-0.06	0.58	-27.03x	2.71x	1.56	1.43	+9.09%	2.35	0.85	2.00	1.56	+28%	BUY
Materials																		
Construction Materials																		
BUACEMENT*	0.43	29%	26%	13%	2.04	2.90	11.34	34.30x	8.77x	99.45	96.00	+1.74%	18.19	4.35	76.13	99.45	-23%	SELL
DANGCEM*	0.66	19%	36%	13%	2.78	17.56	49.19	15.09x	5.39x	270.00	261.00	+1.53%	6.83	43.80	299.15	265.00	+13%	BUY
WAPCO*	0.61	16%	14%	10%	1.42	3.45	24.82	7.15x	0.99x	25.30	24.00	+2.71%	5.60	6.46	38.65	24.65	+57%	BUY
Specialty Chemicals																		
САР	1.43	11%	37%	15%	2.40	2.48	6.76	7.17x	2.63x	17.80	17.80	0.00%	9.49	2.02	19.19	17.80	+8%	HOLD
BERGER	1.14	3%	6%	4%	1.60	0.64	11.31	10.35x	0.59x	6.65	6.00	+10.83%	11.15	0.66	7.30	6.65	+10%	HOLD
Energy																		
CONOIL	2.02	4%	18%	8%	2.33	6.38	35.63	4.16x	0.74x	26.50	26.50	0.00%	5.00	5.19	25.95	26.50	-2%	HOLD
ETERNA	2.07	0%	-1%	0%	4.03	-0.06	10.39	-119.34x	0.69x	7.20	6.65	+7.62%	8.05	0.73	5.88	7.20	-18%	SELL
ARDOVA	1.63	-2%	-29%	-3%	10.96	-2.86	9.82	-6.67x	1.95x	19.10	18.00	+3.80%	22.84	0.68	15.58	19.10	-18%	SELL
MRS	2.39	1%	6%	3%	2.04	3.56	58.95	4.50x	0.27x	16.00	14.10	+13.48%	4.57	3.52	16.11	16.00	+1%	HOLD
SEPLAT	0.26	18%	9%	5%	1.92	113.67	1,244.81	9.68x	0.88x	1,100.00	1,100.00	0.00%	8.87	134.32	1,191.42	1,100.00	+8%	HOLD
TOTAL	1.39	4%	33%	5%	6.54	47.08	141.49	4.51x	1.50x	212.30	193.00	+10.00%	5.07	46.90	237.70	212.30	+12%	BUY
Telecommunications																		
MTNN	0.79	18%	142.68%	14.37%	9.93	17.07	11.96	13.47x	19.22x	229.90	215.00	+6.93%	12.00	25.12	301.42	229.90	+31%	BUY
AIRTELAFRI*	0.38	11%	12%	4%	2.88	49.50	402.93	32.53x	4.00x	1,635.00	1,500.00	-1.53%	4.66	317.84	1,481.13	1,610.00	-8%	HOLD



Equity | Stock Recommendation

*TP calculated with EV/EBITDA multiple.	BVP= Book Value Per Share
TP=Target Price	P/E=Price-to-Earnings
Last Wk. Pr= Last Week Price	AT=Asset Turnover
CP= Current Price	OM=Operating Margin
UPP=Upside Potential	NM= Net Margin
ROE=Return on Equity	ROA=Return on Asset
RT= Rating	Lev=Leverage
Exp. EPS= 2022 Dec Expected EPS	UR=Under Review

Data in the Fundamental columns are based on trailing performance.



EQUITY | STOCK RECOMMENDATION

Analyst's Certification and Disclaimer

This research report has been prepared by the research analyst(s), whose name(s) appear(s) on the cover of this report. Each research analyst hereby certifies, with respect to each security or issuer covers in this research that:

- (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or issuers (the Issuer); and
- (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. Research analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Meristem Securities Limited (the Firm). Like all of the Firm's employees, research analysts receive compensation that is impacted by overall Firm profitability, which includes revenues from other business units within the Firm.
- (3) each research analyst and/or persons connected with any research analyst may have interacted with sales and trading personnel, or similar, for the purpose of gathering, synthesizing and interpreting non-material non-public or material public market information.

As at the date of this report, any ratings, forecasts, estimates, opinions or views herein constitute a judgment, and are not connected to research analysts' compensations. In the case of non-currency of the date of this report, the views and contents may not reflect the research analysts' current thinking. This document has been produced independently of the Issuer. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the ratings, forecasts, estimates, opinions and views contained herein are fair and reasonable, neither the research analysts, the Issuer, nor any of its directors, officers or employees, shall be in any way responsible for the contents hereof, and no reliance should be placed on the accuracy, fairness or completeness of the information contained in this document. No person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith.

Analysts' Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Investment Banking.

Investment Ratings

Fair Value Estimate

We estimate stock's fair value by computing a weighted average of projected prices derived from discounted cash flow and relative valuation methodologies. The choice of relative valuation methodology (ies) usually depends on the firm's peculiar business model and what in the opinion of our analyst is considered as a key driver of the stock's value from a firm specific as well as an industry perspective. However, we attach the most weight to discounted cash flow valuation methodology.

Target Price Estimate

While we believe that the fair value is underpinned by the future benefits stream and growth outlooks, which are primary drivers of value, the market might not align to the fair value estimate within the estimated investment horizon. Thus, we do not derive our target price from the fair value but from a trading perspective using the year projected earnings or book value and the respective target multiples. Notwithstanding, we are of the opinion that the variance between the two should not be too significant.

Ratings Specification

BUY: Target Price of the stock is above the current market price by at least 10 percent

HOLD: Target Price of the stock ranges between **-10 percent and 10 percent** from the current market price.

SELL: Target Price of the stock is more than 10 percent below the current market price.

Definitions

Price Targets: Price targets reflect in part the analyst's estimates for the company's earnings. The achievement of any price target may be impeded by general market and macroeconomic trends, and by other risks related to the company or market and may not occur if the company's earnings fall short of estimates.

Asset allocation: The recommended weighting for equities, cash and fixed income instrument is based on a number of metrics and does not relate to a particular size change in one variable.



Conflict of Interest

It is the policy of Meristem Securities Limited and its subsidiaries and affiliates (Individually and collectively referred to as "Meristem") that research analysts may not be involved in activities that suggest that they are representing the interests of Meristem in a way likely to appear to be inconsistent with providing independent investment research. In addition, research analysts' reporting lines are structured so as to avoid any conflict of interests.

For example, research analysts are not subject to the supervision or control of anyone in Meristem's Investment Banking or Sales and trading departments. However, such sales and trading departments may trade, as principal, on the basis of the research analysts' published research. Therefore, the proprietary interests of those Sales and Trading departments may conflict with your interests.

Important Disclosure

For U.S. persons only: This research report is a product of Meristem Securities, which is the employer of the research analysts who has prepared the research report. The research analysts preparing the research report are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analysts are not subject to supervision by a U.S. broker-dealer, and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Meristem Securities only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

Legal entity disclosures

Meristem Securities Limited is a member of The Nigerian Stock Exchange and is authorized and regulated by the Securities and Exchange Commission to conduct investment banking and financial advisory business in Nigeria. However, **the** company through its subsidiaries carries out stock broking, wealth management, trustees and registrars' businesses which are regulated by the SEC and ICMR.

IMPORTANT INFORMATION: DISCLAIMER

Meristem Securities Limited ("Meristem") equity reports and its attendant recommendations are prepared based on publicly available information and are meant for general information purposes only and it may not be reproduced or distributed to any other person. All reasonable care has been taken to ensure that the information contained herein is not misleading or untrue at the time of publication; Meristem can neither guarantee its accuracy nor completeness as they are an expression of our analysts' views and opinions.

Meristem and any of its associated or subsidiary companies or the employees thereof cannot be held responsible for any loss suffered by relying on the said information as this information as earlier stated, is based on publicly available information, analysts' estimates and opinions, and is meant for general information purposes and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell securities or any financial instruments. The value of any investment is subject to fluctuations, i.e., may fall and rise. Past performance is no guide to the future. The rate of exchange between currencies may cause the value of investment to increase or diminish. Hence investors may not get back the full value of their original investment.

Meristem Securities is registered with the Securities and Exchange (SEC) and is also a member of The Nigerian Stock Exchange (The NSE). Meristem Securities' registered office is at 20A Gerard Road, Ikoyi, Lagos, Nigeria. Website: www.meristemng.com; Email: research@meristemng.com. © Meristem Securities Limited 2023.



EQUITY | STOCK RECOMMENDATION

Contact Information

Brokerage and Retail Services

<u>topeoludimu@meristemng.com</u> (+234 905 569 0627) <u>adaezeonyemachi@meristemng.com</u> (+234 808 369 0213)

contact@meristemng.com

Investment Banking/Corporate Finance

rasakisalawu@meristemng.com (+234 806 022 9889) seunlijofi@meristemng.com (+234 808 536 5766)

Wealth Management

funmilolaadekola-daramola@meristemng.com (+234 805 498 4522) <u>crmwealth@meristemng.com</u> (+234 01 738 9948)

Registrars

oluseyiowoturo@meristemregistrars.com (+234 802 321 0561) martinaosague@meristemregistrars.com (+234 802 303 1783) www.meristemregistrars.com

Tel: +23401-280 9250

Trust Services

damilolahassan@meristemng.com (+234 803 613 9123) trustees@meristemng.com

Group Business Development

saheedbashir@mersitemng.com (+234 802 454 6575) ifeomaanyanwu@meristemng.com (+234 802 394 2967) info@meristemng.com

Meristem Finance

olasokomubo@meristemfinance.com (+234 803 324 7996) mattheawotunde@meristemfinance.com (+234 802 390 6249)

Client Services

adefemitaiwo@meristemng.com (+234 803 694 3034) car@meristemng.com

Investment Research

damilareojo@meristemng.com (+234 816 890 2771)
praiseihansekhien@meristemng.com (+234 817 007 1512)

research@meristemng.com

Corporate websites: www.meristemng.com www.meristemwealth.com www.meristemregistrars.com

Meristem Research can also be accessed on the following platforms:

Meristem Research portal: research.meristemng.com

Bloomberg: MERI <GO>

Capital IQ: www.capitaliq.com Reuters: www.thomsonreuters.com

ISI Emerging Markets: www.securities.com/ch.html?pc=NG FactSet: www.factset.com